Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases

Progress in Retinal and Eye Research

Volumn 34, Issue , 2013, Pages 89-124

  Bock, Felix ^a   Maruyama, Kazuichi ^b   Regenfuss, Birgit ^a   Hos, Deniz ^a   Steven, Philipp ^a   Heindl, Ludwig M ^a   Cursiefen, Claus ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Cornea; Dry eye; Genetic diversity; Inflammation; Keratoplasty; Lymphangiogenesis; Macrophages; Melanoma; Therapeutic concepts; Two photon

Indexed keywords

AGANIRSEN; BEVACIZUMAB; CELECOXIB; CLODRONIC ACID; CORTICOSTEROID; CYTOKINE; FLUOROURACIL; GEFITINIB; PEGAPTANIB; RANIBIZUMAB; THALIDOMIDE; VASCULOTROPIN INHIBITOR;

AGING; ALLERGIC CONJUNCTIVITIS; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CILIARY BODY; CLINICAL PRACTICE; CLINICAL TRIAL; CONJUNCTIVA; CORNEA DISEASE; CORNEA TRANSPLANTATION; DRY EYE; EYE DISEASE; GENETIC VARIABILITY; GLAUCOMA; GRAFT SURVIVAL; HOSPITAL; HUMAN; IMMUNE RESPONSE; KERATOPLASTY; LYMPH VESSEL; LYMPHANGIOGENESIS; MACROPHAGE; MELANOMA; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NEUROTOXICITY; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PTERYGIUM; REVIEW; SQUAMOUS CELL CARCINOMA; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; CONJUNCTIVA; CORNEA; CORNEAL NEOVASCULARIZATION; HUMANS; LIMBUS CORNEAE; LYMPHANGIOGENESIS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84876714654     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2013.01.001     Document Type: Review

References (263)

1. Achen M.G., Stacker S.A. Molecular control of lymphatic metastasis. Annals of the New York Academy of Sciences 2008, 1131:225-234.
2. Aharinejad S., MacDonald I.C., Schmidt E.E., Bock P., Hagen D., Groom A.C. Scanning and transmission electron microscopy and high resolution intravital video-microscopy of capillaries in the mouse exocrine pancreas, with special emphasis on endothelial cells. The Anatomical Record 1993, 237:163-177.
3. Albuquerque R.J., Hayashi T., Cho W.G., Kleinman M.E., Dridi S., Takeda A., Baffi J.Z., Yamada K., Kaneko H., Green M.G., Chappell J., Wilting J., Weich H.A., Yamagami S., Amano S., Mizuki N., Alexander J.S., Peterson M.L., Brekken R.A., Hirashima M., Capoor S., Usui T., Ambati B.K., Ambati J. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nature Medicine 2009, 15:1023-1030.
4. Altenburger A.E., Bachmann B., Seitz B., Cursiefen C. Morphometric analysis of postoperative corneal neovascularization after high-risk keratoplasty: herpetic versus non-herpetic disease. Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2012, 250(11):1663-1671.
5. Ambati B.K., Nozaki M., Singh N., Takeda A., Jani P.D., Suthar T., Albuquerque R.J., Richter E., Sakurai E., Newcomb M.T., Kleinman M.E., Caldwell R.B., Lin Q., Ogura Y., Orecchia A., Samuelson D.A., Agnew D.W., St Leger J., Green W.R., Mahasreshti P.J., Curiel D.T., Kwan D., Marsh H., Ikeda S., Leiper L.J., Collinson J.M., Bogdanovich S., Khurana T.S., Shibuya M., Baldwin M.E., Ferrara N., Gerber H.P., De Falco S., Witta J., Baffi J.Z., Raisler B.J., Ambati J. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006, 443:993-997.
6. Ambati B.K., Patterson E., Jani P., Jenkins C., Higgins E., Singh N., Suthar T., Vira N., Smith K., Caldwell R. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. British Journal of Ophthalmology 2007, 91:505-508.
7. Anshu A., Price M.O., Price F.W. Risk of corneal transplant rejection significantly reduced with Descemet's membrane endothelial keratoplasty. Ophthalmology 2012, 119:536-540.
8. Arimoto J., Ikura Y., Suekane T., Nakagawa M., Kitabayashi C., Iwasa Y., Sugioka K., Naruko T., Arakawa T., Ueda M. Expression of LYVE-1 in sinusoidal endothelium is reduced in chronically inflamed human livers. Journal of Gastroenterology 2010, 45:317-325.
9. Armstrong L.C., Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biology 2003, 22:63-71.
10. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
11. Augustin H.G., Braun K., Telemenakis I., Modlich U., Kuhn W. Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. The American Journal of Pathology 1995, 147:339-351.
12. Bachmann B.O., Bock F., Wiegand S.J., Maruyama K., Dana M.R., Kruse F.E., Luetjen-Drecoll E., Cursiefen C. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Archives of Ophthalmology 2008, 126:71-77.
13. Bachmann B.O., Luetjen-Drecoll E., Bock F., Wiegand S.J., Hos D., Dana R., Kruse F.E., Cursiefen C. Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. British Journal of Ophthalmology 2009, 93:1075-1080.
14. Bachmann B., Taylor R.S., Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 2010, 117:1300-1305. e1307.
15. Bachmann B., Taylor R.S., Cursiefen C. The association between corneal neovascularization and visual acuity: a systematic review. Acta Ophthalmologica 2013, 91(1):12-19.
16. Ballaun C., Weninger W., Uthman A., Weich H., Tschachler E. Human keratinocytes express the three major splice forms of vascular endothelial growth factor. Journal of Investigative Dermatology 1995, 104:7-10.
17. Barbazetto I.A., Lee T.C., Abramson D.H. Treatment of conjunctival squamous cell carcinoma with photodynamic therapy. American Journal of Ophthalmology 2004, 138:183-189.
18. Beasley N.J., Prevo R., Banerji S., Leek R.D., Moore J., van Trappen P., Cox G., Harris A.L., Jackson D.G. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Research 2002, 62(5):1315-1320.
19. Becker B. The side effects of corticosteroids. Investigative Ophthalmology 1964, 3:492-497.
20. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. Journal of Clinical Investigation 1999, 103:159-165.
21. Biozzi G., Ribeiro O.G., Saran A., Araujo M.L., Maria D.A., De Franco M., Cabrera W.K., Sant'anna O.A., Massa S., Covelli V., Mouton D., Neveu T., Siqueira M., Ibanez O.M. Effect of genetic modification of acute inflammatory responsiveness on tumorigenesis in the mouse. Carcinogenesis 1998, 19:337-346.
22. Bock F., Cursiefen C. The Immunological Aspects of Aqueous Humor Turnover. Encyclopedia of the Eye 2010.
23. Bock F., Onderka J., Dietrich T., Bachmann B., Kruse F.E., Paschke M., Zahn G., Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Investigative Ophthalmology & Visual Science 2007, 48:2545-2552.
24. Bock F., Konig Y., Kruse F., Baier M., Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2008, 246:281-284.
25. Bock F., Onderka J., Dietrich T., Bachmann B., Pytowski B., Cursiefen C. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2008, 246:115-119.
26. Bock F., Onderka J., Rummelt C., Dietrich T., Bachmann B., Kruse F.E., Schlotzer-Schrehardt U., Cursiefen C. Safety profile of topical VEGF neutralization at the cornea. Investigative Ophthalmology & Visual Science 2009, 50:2095-2102.
27. Bock F., Regenfuss B., Cursiefen C. Antiangiogenic therapy at the ocular surface: when, what and why?. Ophthalmologe 2011, 108:230-236.
28. Bourghardt Peebo B., Fagerholm P., Traneus-Rockert C., Lagali N. Time-lapse in vivo imaging of corneal angiogenesis: the role of inflammatory cells in capillary sprouting. Investigative Ophthalmology & Visual Science 2011, 52:3060-3068.
29. Bucher F., Parthasarathy A., Bergua A., Onderka J., Regenfuss B., Cursiefen C., Bock F. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis. Acta Ophthalmologica 2012, 10.1111/j.1755-3768.2012.02525.x.
30. Buttler K., Ezaki T., Wilting J. Proliferating mesodermal cells in murine embryos exhibiting macrophage and lymphendothelial characteristics. BMC Developmental Biology 2008, 8:43.
31. Byzova T.V., Goldman C.K., Jankau J., Chen J., Cabrera G., Achen M.G., Stacker S.A., Carnevale K.A., Siemionow M., Deitcher S.R., DiCorleto P.E. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood 2002, 99:4434-4442.
32. Cao W., Tombran-Tink J., Elias R., Sezate S., Mrazek D., McGinnis J.F. In vivo protection of photoreceptors from light damage by pigment epithelium-derived factor. Investigative Ophthalmology & Visual Science 2001, 42:1646-1652.
33. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
34. Chan C.K., Pham L.N., Chinn C., Spee C., Ryan S.J., Akhurst R.J., Hinton D.R. Mouse strain-dependent heterogeneity of resting limbal vasculature. Investigative Ophthalmology & Visual Science 2004, 45:441-447.
35. Chan C.K., Pham L.N., Zhou J., Spee C., Ryan S.J., Hinton D.R. Differential expression of pro- and antiangiogenic factors in mouse strain-dependent hypoxia-induced retinal neovascularization. Laboratory Investigation; a Journal of Technical Methods and Pathology 2005, 85:721-733.
36. Chang J.H., Gabison E.E., Kato T., Azar D.T. Corneal neovascularization. Current Opinion in Ophthalmology 2001, 12:242-249.
37. Charles P.C., Weber K.S., Cipriani B., Brosnan C.F. Cytokine, chemokine and chemokine receptor mRNA expression in different strains of normal mice: implications for establishment of a Th1/Th2 bias. Journal of Neuroimmunology 1999, 100:64-73.
38. Chauhan S.K., Jin Y., Goyal S., Lee H.S., Fuchsluger T.A., Lee H.K., Dana R. A novel pro-lymphangiogenic function for Th17/IL-17. Blood 2011, 118(17):4630-4634.
39. Chen H., Ikeda U., Shimpo M., Maeda Y., Shibuya M., Ozawa K., Shimada K. Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene. Journal of Cardiovascular Pharmacology 2000, 36:498-502.
40. Chen L., Cursiefen C., Barabino S., Zhang Q., Dana M.R. Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. Investigative Ophthalmology & Visual Science 2005, 46:4536-4540.
41. Chinnery H.R., Humphries T., Clare A., Dixon A.E., Howes K., Moran C.B., Scott D., Zakrzewski M., Pearlman E., McMenamin P.G. Turnover of bone marrow-derived cells in the irradiated mouse cornea. Immunology 2008, 125:541-548.
42. Chinnery H.R., Pearlman E., McMenamin P.G. Cutting edge: membrane nanotubes in vivo: a feature of MHC class II+ cells in the mouse cornea. Journal of Immunology 2008, 180:5779-5783.
43. Cimpean A.M., Poenaru Sava M., Raica M., Ribatti D. Preliminary evidence of the presence of lymphatic vessels immunoreactive for D2-40 and Prox-1 in human pterygium. Oncology Reports 2011, 26:1111-1113.
44. Clarijs R., Schalkwijk L., Ruiter D.J., de Waal R.M. Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma. Investigative Ophthalmology & Visual Science 2001, 42:1422-1428.
45. Cloutier F., Lawrence M., Goody R., Lamoureux S., Al-Mahmood S., Colin S., Ferry A., Conduzorgues J.P., Hadri A., Cursiefen C., Udaondo P., Viaud E., Thorin E., Chemtob S. Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration. Investigative Ophthalmology & Visual Science 2012, 53:1195-1203.
46. Cogan D.G. Vascularization of the cornea. Its experimental induction by small lesions and a new theory of its pathogenesis. Transactions of the American Ophthalmological Society 1948, 46:457-471.
47. Cunningham M.A., Edelman J.L., Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Survey of Ophthalmology 2008, 53:139-149.
48. Cursiefen C., Heindl L.M. Perspectives of deep anterior lamellar keratoplasty. Ophthalmologe 2011, 108:833-839.
49. Cursiefen C., Kuchle M., Naumann G.O. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1998, 17:611-613.
50. Cursiefen C., Rummelt C., Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 2000, 19:526-533.
51. Cursiefen C., Wenkel H., Martus P., Langenbucher A., Nguyen N.X., Seitz B., Kuchle M., Naumann G.O. Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2001, 239:514-521.
52. Cursiefen C., Martus P., Nguyen N.X., Langenbucher A., Seitz B., Kuchle M. Corneal neovascularization after nonmechanical versus mechanical corneal trephination for non-high-risk keratoplasty. Cornea 2002, 21:648-652.
53. Cursiefen C., Schlotzer-Schrehardt U., Kuchle M., Sorokin L., Breiteneder-Geleff S., Alitalo K., Jackson D. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Investigative Ophthalmology & Visual Science 2002, 43:2127-2135.
54. Cursiefen C., Chen L., Dana M.R., Streilein J.W. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea 2003, 22:273-281.
55. Cursiefen C., Hofmann-Rummelt C., Kuchle M., Schlotzer-Schrehardt U. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. British Journal of Ophthalmology 2003, 87:101-106.
56. Cursiefen C., Seitz B., Dana M.R., Streilein J.W. Angiogenesis and lymphangiogenesis in the cornea. Pathogenesis, clinical implications and treatment options. Ophthalmologe 2003, 100:292-299.
57. Cursiefen C., Cao J., Chen L., Liu Y., Maruyama K., Jackson D., Kruse F.E., Wiegand S.J., Dana M.R., Streilein J.W. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Investigative Ophthalmology & Visual Science 2004, 45:2666-2673.
58. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejewski C., D'Amore P.A., Dana M.R., Wiegand S.J., Streilein J.W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. Journal of Clinical Investigation 2004, 113:1040-1050.
59. Cursiefen C., Masli S., Ng T.F., Dana M.R., Bornstein P., Lawler J., Streilein J.W. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Investigative Ophthalmology & Visual Science 2004, 45:1117-1124.
60. Cursiefen C., Ikeda S., Nishina P.M., Smith R.S., Ikeda A., Jackson D., Mo J.S., Chen L., Dana M.R., Pytowski B., Kruse F.E., Streilein J.W. Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling. American Journal of Pathology 2005, 166(5):1367-1377.
61. Cursiefen C., Chen L., Saint-Geniez M., Hamrah P., Jin Y., Rashid S., Pytowski B., Persaud K., Wu Y., Streilein J.W., Dana R. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:11405-11410.
62. Cursiefen C., Maruyama K., Jackson D.G., Streilein J.W., Kruse F.E. Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 2006, 25:443-447.
63. Cursiefen C., Rummelt C., Junemann A., Vorwerk C., Neuhuber W., Kruse F.E., Schroedl F. Absence of blood and lymphatic vessels in the developing human cornea. Cornea 2006, 25:722-726.
64. Cursiefen C., Bock F., Horn F.K., Kruse F.E., Seitz B., Borderie V., Fruh B., Thiel M.A., Wilhelm F., Geudelin B., Descohand I., Steuhl K.P., Hahn A., Meller D. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 2009, 116:1630-1637.
65. Cursiefen C., Maruyama K., Bock F., Saban D., Sadrai Z., Lawler J., Dana R., Masli S. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. Journal of Experimental Medicine 2011, 208:1083-1092.
66. Cursiefen C., Colin J., Dana R., Diaz-Llopis M., Faraj L.A., Garcia-Delpech S., Geerling G., Price F.W., Remeijer L., Rouse B.T., Seitz B., Udaondo P., Meller D., Dua H. Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. British Journal of Ophthalmology 2012, 96:3-9.
67. Cursiefen C. Immune privilege and angiogenic privilege of the cornea. Chemical Immunology and Allergy 2007, 92:50-57.
68. Dadras S.S., Paul T., Bertoncini J., Brown L.F., Muzikansky A., Jackson D.G., Ellwanger U., Garbe C., Mihm M.C., Detmar M. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. The American Journal of Pathology 2003, 162:1951-1960.
69. Dana M.R., Streilein J.W. Loss and restoration of immune privilege in eyes with corneal neovascularization. Investigative Ophthalmology & Visual Science 1996, 37:2485-2494.
70. Darrell R.W. Follicular conjunctivitis. Viral Diseases of the Eye 1985, 296-311. Lea & Febiger, Philadelphia. R.W. Darrell (Ed.).
71. Dastjerdi M.H., Sadrai Z., Saban D.R., Zhang Q., Dana R. Corneal penetration of topical and subconjunctival bevacizumab. Investigative Ophthalmology & Visual Science 2011, 52:8718-8723.
72. De Paiva C.S., Villarreal A.L., Corrales R.M., Rahman H.T., Chang V.Y., Farley W.J., Stern M.E., Niederkorn J.Y., Li D.Q., Pflugfelder S.C. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. Investigative Ophthalmology & Visual Science 2007, 48:2553-2560.
73. De Paiva C.S., Chotikavanich S., Pangelinan S.B., Pitcher J.D., Fang B., Zheng X., Ma P., Farley W.J., Siemasko K.F., Niederkorn J.Y., Stern M.E., Li D.Q., Pflugfelder S.C. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunology 2009, 2:243-253.
74. Dickerson J.E., Dotzel E., Clark A.F. Steroid-induced cataract: new perspective from in vitro and lens culture studies. Experimental Eye Research 1997, 65:507-516.
75. Dietrich T., Onderka J., Bock F., Kruse F.E., Vossmeyer D., Stragies R., Zahn G., Cursiefen C. Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. The American Journal of Pathology 2007, 171:361-372.
76. Dietrich T., Bock F., Yuen D., Hos D., Bachmann B.O., Zahn G., Wiegand S., Chen L., Cursiefen C. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. Journal of Immunology 2010, 184:535-539.
77. Dithmar S., Diaz C.E., Grossniklaus H.E. Intraocular melanoma spread to regional lymph nodes: report of two cases. Retina 2000, 20:76-79.
78. Ecoiffier T., Yuen D., Chen L. Differential distribution of blood and lymphatic vessels in the murine cornea. Investigative Ophthalmology & Visual Science 2010, 51(5):2436-2440.
79. Eliason J.A., Elliott J.P. Proliferation of vascular endothelial cells stimulated in vitro by corneal epithelium. Investigative Ophthalmology & Visual Science 1987, 28:1963-1969.
80. Eliason J.A. Leukocytes and experimental corneal vascularization. Investigative Ophthalmology & Visual Science 1978, 17:1087-1095.
81. Fallah M.R., Khosravi K., Hashemian M.N., Beheshtnezhad A.H., Rajabi M.T., Gohari M. Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Current Eye Research 2010, 35:17-22.
82. Finger P.T., Chin K.J. Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study. Ophthalmic Plastic and Reconstructive Surgery 2012, 28:85-89.
83. Folkman J. Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine 1971, 285:1182-1186.
84. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Annals of Surgery 1972, 175:409-416.
85. Foroutan A., Fariba B., Pejman B., Mahmoud J., Khalil G.F., Arash E.A., Foroutan P. Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty. Cornea 2010, 29:1268-1272.
86. Fukumoto A., Maruyama K., Walsh T., Kajiya K., Hamuro J., D'Amore P.A., Kinoshita S. Intracellular thiol redox status regulates lymphangiogenesis and dictates corneal limbal graft survival. Investigative Ophthalmology & Visual Science 2010, 51:2450-2458.
87. Gabison E., Chang J.H., Hernandez-Quintela E., Javier J., Lu P.C., Ye H., Kure T., Kato T., Azar D.T. Anti-angiogenic role of angiostatin during corneal wound healing. Experimental Eye Research 2004, 78:579-589.
88. Galor A., Yoo S.H., Piccoli F.V., Schmitt A.J., Chang V., Perez V.L. Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. American Journal of Ophthalmology 2010, 149:926-931. e922.
89. Gehlsen U., Huttmann G., Steven P. Intravital multidimensional real-time imaging of the conjunctival immune system. Developments in Ophthalmology 2010, 45:40-48.
90. Gottschalk K., Rummelt C., Cursiefen C. Conjunctival chemosis resistant to therapy. Klin Monbl Augenheilkd 2006, 223:696-698.
91. Goyal S., Chauhan S.K., El Annan J., Nallasamy N., Zhang Q., Dana R. Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?. Archives of Ophthalmology 2010, 128:819-824.
92. Goyal S., Chauhan S.K., Dana R. Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease. Archives of Ophthalmology 2011, 130:84-89.
93. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 270:1189-1192.
94. Guo W., Zhu Y., Yu P.K., Yu X., Sun X., Cringle S.J., Su E.N., Yu D.Y. Quantitative study of the topographic distribution of conjunctival lymphatic vessels in the monkey. Experimental Eye Research 2012, 94:90-97.
95. Hamrah P., Zhang Q., Liu Y., Dana M.R. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Investigative Ophthalmology & Visual Science 2002, 43:639-646.
96. Hamrah P., Liu Y., Zhang Q., Dana M.R. The corneal stroma is endowed with a significant number of resident dendritic cells. Investigative Ophthalmology & Visual Science 2003, 44:581-589.
97. Hamrah P., Chen L., Cursiefen C., Zhang Q., Joyce N.C., Dana M.R. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva. Experimental Eye Research 2004, 79:553-561.
98. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
99. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
100. Hashemian M.N., Zare M.A., Rahimi F., Mohammadpour M. Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique. Cornea 2011, 30:215-218.
101. Hattori T., Chauhan S.K., Lee H., Ueno H., Dana R., Kaplan D.H., Saban D.R. Characterization of Langerin-expressing dendritic cell subsets in the normal cornea. Investigative Ophthalmology & Visual Science 2011, 52:4598-4604.
102. He Y.G., Ross J., Niederkorn J.Y. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Investigative Ophthalmology & Visual Science 1991, 32:2723-2728.
103. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. Journal of the National Cancer Institute 2002, 94:819-825.
104. Heidenreich R., Rocken M., Ghoreschi K. Angiogenesis: the new potential target for the therapy of psoriasis?. Drug News and Perspectives 2008, 21:97-105.
105. Heiligenhaus A., Cursiefen C. Special topic " inflammations of the eye in inflammatory systemic diseases" . Klin Monbl Augenheilkd 2011, 228:411-412.
106. Heindl L.M., Cursiefen C. Pterygium. Etiology, clinical aspects and novel adjuvant therapies. Ophthalmologe 2010, 107. 517-520, 522-514.
107. Heindl L.M., Cursiefen C. Retained Descemet's membrane after penetrating keratoplasty for macular corneal dystrophy. Ophthalmologe 2010, 107:55-59.
108. Heindl L.M., Hofmann T.N., Knorr H.L., Rummelt C., Schrodl F., Schlotzer-Schrehardt U., Holbach L.M., Naumann G.O., Kruse F.E., Cursiefen C. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. Investigative Ophthalmology & Visual Science 2009, 50:1988-1995.
109. Heindl L.M., Hofmann-Rummelt C., Adler W., Holbach L.M., Naumann G.O., Kruse F.E., Cursiefen C. Tumor-associated lymphangiogenesis in the development of conjunctival squamous cell carcinoma. Ophthalmology 2010, 117:649-658.
110. Heindl L.M., Hofmann T.N., Adler W., Knorr H.L., Holbach L.M., Naumann G.O., Kruse F.E., Cursiefen C. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension?. Ophthalmology 2010, 117:334-342.
111. Heindl L.M., Hofmann T.N., Schrodl F., Holbach L.M., Kruse F.E., Cursiefen C. Intraocular lymphatics in ciliary body melanomas with extraocular extension: functional for lymphatic spread?. Archives of Ophthalmology 2010, 128:1001-1008.
112. Heindl L.M., Hofmann-Rummelt C., Adler W., Bosch J.J., Holbach L.M., Naumann G.O., Kruse F.E., Cursiefen C. Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva. Ophthalmology 2011, 118:2351-2360.
113. Heindl L.M., Hofmann-Rummelt C., Adler W., Bosch J.J., Holbach L.M., Naumann G.O., Kruse F.E., Cursiefen C. Tumor-associated lymphangiogenesis in the development of conjunctival melanoma. Investigative Ophthalmology & Visual Science 2011, 52:7074-7083.
114. Heindl L.M., Riss S., Bachmann B.O., Laaser K., Kruse F.E., Cursiefen C. Split cornea transplantation for 2 recipients: a new strategy to reduce corneal tissue cost and shortage. Ophthalmology 2011, 118:294-301.
115. Heindl L.M., Riss S., Laaser K., Bachmann B.O., Kruse F.E., Cursiefen C. Split cornea transplantation for 2 recipients - review of the first 100 consecutive patients. American Journal of Ophthalmology 2011, 152:523-532. e522.
116. Hos D., Bachmann B., Bock F., Onderka J., Cursiefen C. Age-related changes in murine limbal lymphatic vessels and corneal lymphangiogenesis. Experimental Eye Research 2008, 87:427-432.
117. Hos D., Bock F., Dietrich T., Onderka J., Kruse F.E., Thierauch K.H., Cursiefen C. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Investigative Ophthalmology & Visual Science 2008, 49:1836-1842.
118. Hos D., Regenfuss B., Bock F., Onderka J., Cursiefen C. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis. Investigative Ophthalmology & Visual Science 2011, 52:5778-5785.
119. Hos D., Saban D.R., Bock F., Regenfuss B., Onderka J., Masli S., Cursiefen C. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Archives of Ophthalmology 2011, 129:445-452.
120. How A., Chua J.L., Charlton A., Su R., Lim M., Kumar R.S., Crowston J.G., Wong T.T. Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Investigative Ophthalmology & Visual Science 2010, 51:928-932.
121. Hughes A.D., Thom S.A., Woodall N., Schachter M., Hair W.M., Martin G.N., Sever P.S. Human vascular responses to endothelin-1: observations in vivo and in vitro. Journal of Cardiovascular Pharmacology 1989, 13(Suppl. 5):S225-S228.
122. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:9265-9269.
123. Iwata C., Kano M.R., Komuro A., Oka M., Kiyono K., Johansson E., Morishita Y., Yashiro M., Hirakawa K., Kaminishi M., Miyazono K. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Research 2007, 67:10181-10189.
124. Jager M.J. Corneal Langerhans cells and ocular immunology. Regional Immunology 1992, 4:186-195.
125. Jarrin E., Ruiz-Casas D., Mendivil A. Efficacy of bevacizumab against interface neovascularization after deep anterior lamellar keratoplasty. Cornea 2012, 31:188-190.
126. Jeltsch M., Kaipainen A., Joukov V., Meng X., Lakso M., Rauvala H., Swartz M., Fukumura D., Jain R.K., Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997, 276:1423-1425.
127. Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nature Medicine 2000, 6:41-48.
128. Johnson L.A., Prevo R., Clasper S., Jackson D.G. Inflammation-induced uptake and degradation of the lymphatic endothelial hyaluronan receptor LYVE-1. The Journal of Biological Chemistry 2007, 282:33671-33680.
129. Kaminski M., Kaminska G. Inhibition of lymphocyte-induced angiogenesis by enzymatically isolated rabbit cornea cells. Archivum Immunologiae et Therapiae Experimentalis (Warsz) 1978, 26:1079-1082.
130. Karkkainen M.J., Petrova T.V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000, 19:5598-5605.
131. Kato T., Kure T., Chang J.H., Gabison E.E., Itoh T., Itohara S., Azar D.T. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Letters 2001, 508:187-190.
132. Kato T., Chang J.H., Azar D.T. Expression of type XVIII collagen during healing of corneal incisions and keratectomy wounds. Investigative Ophthalmology & Visual Science 2003, 44:78-85.
133. Kenyon B.M., Voest E.E., Chen C.C., Flynn E., Folkman J., D'Amato R.J. A model of angiogenesis in the mouse cornea. Investigative Ophthalmology & Visual Science 1996, 37:1625-1632.
134. Khodadoust A.A., Silverstein A.M. Transplantation and rejection of individual cell layers of the cornea. Investigative Ophthalmology 1969, 8:180-195.
135. Kim Y.M., Hwang S., Kim Y.M., Pyun B.J., Kim T.Y., Lee S.T., Gho Y.S., Kwon Y.G. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. Journal of Biological Chemistry 2002, 277:27872-27879.
136. Kim T.I., Chung J.L., Hong J.P., Min K., Seo K.Y., Kim E.K. Bevacizumab application delays epithelial healing in rabbit cornea. Investigative Ophthalmology & Visual Science 2009, 50:4653-4659.
137. Koenig Y., Bock F., Horn F., Kruse F., Straub K., Cursiefen C. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2009, 247:1375-1382.
138. Koenig Y., Bock F., Kruse F.E., Stock K., Cursiefen C. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs. Cornea 2012, 31(8):887-892.
139. Kriehuber E., Breiteneder-Geleff S., Groeger M., Soleiman A., Schoppmann S.F., Stingl G., Kerjaschki D., Maurer D. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. Journal of Experimental Medicine 2001, 194:797-808.
140. Kuhlmann A., Amann K., Schlotzer-Schrehardt U., Kruse F.E., Cursiefen C. Endothelin-1 and ETA/ETB receptor protein and mRNA: expression in normal and vascularized human corneas. Cornea 2005, 24:837-844.
141. Kure T., Chang J.H., Kato T., Hernandez-Quintela E., Ye H., Lu P.C., Matrisian L.M., Gatinel D., Shapiro S., Gosheh F., Azar D.T. Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice. Investigative Ophthalmology & Visual Science 2003, 44:137-144.
142. Lam V.M., Nguyen N.X., Martus P., Seitz B., Kruse F.E., Cursiefen C. Surgery-related factors influencing corneal neovascularization after low-risk keratoplasty. American Journal of Ophthalmology 2006, 141:260-266.
143. Langham M. Observations on the growth of blood vessels into the cornea; application of a new experimental technique. British Journal of Ophthalmology 1953, 37:210-222.
144. Lawler J. The functions of thrombospondin-1 and-2. Current Opinion in Cell Biology 2000, 12:634-640.
145. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. Journal of Cellular and Molecular Medicine 2002, 6:1-12.
146. Lee G.A., Hirst L.W. Ocular surface squamous neoplasia. Survey of Ophthalmology 1995, 39:429-450.
147. Lekhanont K., Patarakittam T., Thongphiew P., Suwan-apichon O., Hanutsaha P. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea 2012, 31:155-161.
148. Levene R., Shapiro A., Baum J. Experimental corneal vascularization. Archives of Ophthalmology 1963, 70:242-249.
149. Li Q., Peng B., Whitcup S.M., Jang S.U., Chan C.C. Endotoxin induced uveitis in the mouse: susceptibility and genetic control. Experimental Eye Research 1995, 61:629-632.
150. Lin H.C., Chang J.H., Jain S., Gabison E.E., Kure T., Kato T., Fukai N., Azar D.T. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Investigative Ophthalmology & Visual Science 2001, 42:2517-2524.
151. Lin C.T., Hu F.R., Kuo K.T., Chen Y.M., Chu H.S., Lin Y.H., Chen W.L. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency. Investigative Ophthalmology & Visual Science 2010, 51:6277-6285.
152. Liu Y., Hamrah P., Zhang Q., Taylor A.W., Dana M.R. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. Journal of Experimental Medicine 2002, 195:259-268.
153. Liu F., Smith J., Zhang Z., Cole R., Herron B.J. Genetic heterogeneity of skin microvasculature. Developmental Biology 2010, 340:480-489.
154. Longatto-Filho A., Pinheiro C., Pereira S.M., Etlinger D., Moreira M.A., Jube L.F., Queiroz G.S., Baltazar F., Schmitt F.C. Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive and invasive lesions of the uterine cervix. Gynecologic Oncology 2007, 107:45-51.
155. Ma D.H., Tsai R.J., Chu W.K., Kao C.H., Chen J.K. Inhibition of vascular endothelial cell morphogenesis in cultures by limbal epithelial cells. Investigative Ophthalmology & Visual Science 1999, 40:1822-1828.
156. Ma D.H., Chen H.C., Lai J.Y., Sun C.C., Wang S.F., Lin K.K., Chen J.K. Matrix revolution: molecular mechanism for inflammatory corneal neovascularization and restoration of corneal avascularity by epithelial stem cell transplantation. The Ocular Surface 2009, 7:128-144.
157. Maguire M.G., Stark W.J., Gottsch J.D., Stulting R.D., Sugar A., Fink N.E., Schwartz A. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology 1994, 101:1536-1547.
158. Maharaj A.S., Saint-Geniez M., Maldonado A.E., D'Amore P.A. Vascular endothelial growth factor localization in the adult. The American Journal of Pathology 2006, 168:639-648.
159. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., Cao Y., Berkenstam A., Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001, 414:550-554.
160. Maruyama K., Ii M., Cursiefen C., Jackson D.G., Keino H., Tomita M., Van Rooijen N., Takenaka H., D'Amore P.A., Stein-Streilein J., Losordo D.W., Streilein J.W. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. Journal of Clinical Investigation 2005, 115:2363-2372.
161. Maruyama K., Asai J., Ii M., Thorne T., Losordo D.W., D'Amore P.A. Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. The American Journal of Pathology 2007, 170:1178-1191.
162. Maruyama K., Nakazawa T., Cursiefen C., Maruyama Y., Van Rooijen N., D'Amore P.A., Kinoshita S. The maintenance of lymphatic vessels in the cornea is dependent on the presence of macrophages. Investigative Ophthalmology & Visual Science 2012, 53(6):3145-3153.
163. Massingale M.L., Li X., Vallabhajosyula M., Chen D., Wei Y., Asbell P.A. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009, 28:1023-1027.
164. Mastyugin V., Mosaed S., Bonazzi A., Dunn M.W., Schwartzman M.L. Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Current Eye Research 2001, 23:1-10.
165. Matsuda A., Ebihara N., Yokoi N., Maruyama K., Hamuro J., Kinoshita S., Murakami A. Lymphoid neogenesis in the giant papillae of patients with chronic allergic conjunctivitis. Journal of Allergy and Clinical Immunology 2010, 126(6):1310-1312. e1311.
166. Meyer C., Notari L., Becerra S.P. Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. The Journal of Biological Chemistry 2002, 277:45400-45407.
167. Meyer P.A. The circulation of the human limbus. Eye 1989, 3:121-127.
168. Mimura T., Amano S., Usui T., Kaji Y., Oshika T., Ishii Y. Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis. Experimental Eye Research 2001, 72:71-78.
169. Moulton K.S., Melder R.J., Dharnidharka V.R., Hardin-Young J., Jain R.K., Briscoe D.M. Angiogenesis in the huPBL-SCID model of human transplant rejection. Transplantation 1999, 67:1626-1631.
170. Murakami M., Iwai S., Hiratsuka S., Yamauchi M., Nakamura K., Iwakura Y., Shibuya M. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 2006, 108:1849-1856.
171. Murakami M., Zheng Y., Hirashima M., Suda T., Morita Y., Ooehara J., Ema H., Fong G.H., Shibuya M. VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28:658-664.
172. Murata Y., Yamashita A., Saito T., Sugamura K., Hamuro J. The conversion of redox status of peritoneal macrophages during pathological progression of spontaneous inflammatory bowel disease in Janus family tyrosine kinase 3(-/-) and IL-2 receptor gamma(-/-) mice. International Immunology 2002, 14:627-636.
173. Nakao S., Kuwano T., Tsutsumi-Miyahara C., Ueda S., Kimura Y.N., Hamano S., Sonoda K.H., Saijo Y., Nukiwa T., Strieter R.M., Ishibashi T., Kuwano M., Ono M. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. The Journal of Clinical Investigation 2005, 115:2979-2991.
174. Nakao S., Hata Y., Miura M., Noda K., Kimura Y.N., Kawahara S., Kita T., Hisatomi T., Nakazawa T., Jin Y., Dana M.R., Kuwano M., Ono M., Ishibashi T., Hafezi-Moghadam A. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. The American Journal of Pathology 2007, 171:1058-1065.
175. Nakao S., Maruyama K., Zandi S., Melhorn M.I., Taher M., Noda K., Nusayr E., Doetschman T., Hafezi-Moghadam A. Lymphangiogenesis and angiogenesis: concurrence and/or dependence? Studies in inbred mouse strains. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2010, 24:504-513.
176. Nakao S., Zandi S., Faez S., Kohno R., Hafezi-Moghadam A. Discontinuous LYVE-1 expression in corneal limbal lymphatics: dual function as microvalves and immunological hot spots. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2012, 26:808-817.
177. Nakayasu K., Hayashi N., Okisaka S., Sato N. Formation of capillary-like tubes by vascular endothelial cells cocultivated with keratocytes. Investigative Ophthalmology & Visual Science 1992, 33:3050-3057.
178. Niederkorn J.Y., Larkin D.F. Immune privilege of corneal allografts. Ocular Immunology and Inflammation 2010, 18:162-171.
179. Niederkorn J.Y., Mayhew E., He Y. Alloantigens introduced into the anterior chamber of the eye induce systemic suppression of delayed hypersensitivity to third-party alloantigens through " linked recognition" . Transplantation 1995, 60:348-354.
180. Niederkorn J.Y., Stern M.E., Pflugfelder S.C., De Paiva C.S., Corrales R.M., Gao J., Siemasko K. Desiccating stress induces T cell-mediated Sjogren's syndrome-like lacrimal keratoconjunctivitis. Journal of Immunology 2006, 176:3950-3957.
181. Nilforushan N., Yadgari M., Kish SK., Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. American Journal of Ophthalmology 2012, 153(2):352-357. e1.
182. Owman C., Edvinsson L., Hardebo J.E., Groschel-Stewart U., Unsicker D., Walles B. Immunohistochemical demonstration of actin and myosin in brain capillaries. Advances in Neurology 1978, 20:35-37.
183. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., Choi N.C., Mathisen D., Wain J., Mark E.J., Munn L.L., Jain R.K. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
184. Panda A., Vanathi M., Kumar A., Dash Y., Priya S. Corneal graft rejection. Survey of Ophthalmology 2007, 52:375-396.
185. Peebo B.B., Fagerholm P., Traneus-Rockert C., Lagali N. Cellular-level characterization of lymph vessels in live, unlabeled corneas by in vivo confocal microscopy. Investigative Ophthalmology & Visual Science 2009, 51:830-835.
186. Pepose J.S., Leib D.A., Stuart P.M., Easty E.L. Herpes Simplex Virus Disease: Anterior Segment of the Eye 1996, Mosby-Year-Book, St. Louis, MO.
187. Petris C.K., Golomb M., Phillips T.E. Bacterial transcytosis across conjunctival M cells. Investigative Ophthalmology & Visual Science 2007, 48:2172-2177.
188. Pillai C.T., Dua H.S., Hossain P. Fine needle diathermy occlusion of corneal vessels. Investigative Ophthalmology & Visual Science 2000, 41:2148-2153.
189. Platonova, N., Miquel, G., Regenfuss, B., Taouji, S., Cursiefen, C., Chevet, E., Bikfalvi, A. Evidence for the interaction of fibroblast growth factor-2 with the lymphatic endothelial cell marker LYVE-1. Blood, in press.
190. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
191. Ragan D.M., Schmidt E.E., MacDonald I.C., Groom A.C. Spontaneous cyclic contractions of the capillary wall in vivo, impeding red cell flow: a quantitative analysis. Evidence for endothelial contractility. Microvascular Research 1988, 36:13-30.
192. Regenfuss B., Cursiefen C. Concept of angiogenic privilege. Encyclopedia of the Eye 2010, D.A. Dartt, J. Besharse, R. Dana (Eds.).
193. Regenfuss B., Bock F., Parthasarathy A., Cursiefen C. Corneal (lymph)angiogenesis - from bedside to bench and back: a tribute to Judah Folkman. Lymphatic Research and Biology 2008, 6:191-201.
194. Regenfuss B., Onderka J., Bock F., Hos D., Maruyama K., Cursiefen C. Genetic heterogeneity of lymphangiogenesis in different mouse strains. The American Journal of Pathology 2010, 177:501-510.
195. Riss S., Heindl L.M., Bachmann B.O., Kruse F.E., Cursiefen C. Pentacam-based big bubble deep anterior lamellar keratoplasty in patients with keratoconus. Cornea 2012, 31(6):627-632.
196. Rivard A., Fabre J.E., Silver M., Chen D., Murohara T., Kearney M., Magner M., Asahara T., Isner J.M. Age-dependent impairment of angiogenesis. Circulation 1999, 99:111-120.
197. Rogers M.S., Rohan R.M., Birsner A.E., D'Amato R.J. Genetic loci that control vascular endothelial growth factor-induced angiogenesis. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2003, 17:2112-2114.
198. Rogers M.S., Rohan R.M., Birsner A.E., D'Amato R.J. Genetic loci that control the angiogenic response to basic fibroblast growth factor. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2004, 18:1050-1059.
199. Rohan R.M., Fernandez A., Udagawa T., Yuan J., D'Amato R.J. Genetic heterogeneity of angiogenesis in mice. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2000, 14:871-876.
200. Rovenska E., Rovensky J. Lymphatic vessels: structure and function. The Israel Medical Association Journal: IMAJ 2011, 13:762-768.
201. Rymarchyk S.L., Lowenstein H., Mayette J., Foster S.R., Damby D.E., Howe I.W., Aktan I., Meyer R.E., Poynter M.E., Boyson J.E. Widespread natural variation in murine natural killer T-cell number and function. Immunology 2008, 125:331-343.
202. Saban D.R., Cornelius J., Masli S., Schwartzkopff J., Doyle M., Chauhan S.K., Peck A.B., Grant M.B. The role of ACAID and CD4+CD25+FOXP3+ regulatory T cells on CTL function against MHC alloantigens. Molecular Vision 2008, 14:2435-2442.
203. Saban D.R., Bock F., Chauhan S.K., Masli S., Dana R. Thrombospondin-1 derived from APCs regulates their capacity for allosensitization. Journal of Immunology 2010, 185:4691-4697.
204. Sadoun E., Reed M.J. Impaired angiogenesis in aging is associated with alterations in vessel density, matrix composition, inflammatory response, and growth factor expression. Journal of Histochemistry & Cytochemistry 2003, 51:1119-1130.
205. Salven P., Mustjoki S., Alitalo R., Alitalo K., Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003, 101:168-172.
206. Saxena S., Kishore P., Pandey S., Khattri M., Kumar D. Topical bevacizumab for corneal neovascularization after penetrating keratoplasty. European Journal of Ophthalmology 2009, 19:870-872.
207. Schaumburg C.S., Siemasko K.F., De Paiva C.S., Wheeler L.A., Niederkorn J.Y., Pflugfelder S.C., Stern M.E. Ocular surface APCs are necessary for autoreactive T cell-mediated experimental autoimmune lacrimal keratoconjunctivitis. Journal of Immunology 2011, 187:3653-3662.
208. Schloetzer-Schrehardt U., Kruse F.E. Identification and characterization of limbal stem cells. Experimental Eye Research 2005, 81:247-264.
209. Schoppmann S.F., Birner P., Stockl J., Kalt R., Ullrich R., Caucig C., Kriehuber E., Nagy K., Alitalo K., Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. The American Journal of Pathology 2002, 161:947-956.
210. Schroedl F., Brehmer A., Neuhuber W.L., Kruse F.E., May C.A., Cursiefen C. The normal human choroid is endowed with a significant number of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1)-positive macrophages. Investigative Ophthalmology & Visual Science 2008, 49:5222-5229.
211. Sener E., Yuksel N., Yildiz D.K., Yilmaz B., Ozdemir O., Caglar Y., Degirmenci E. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Current Eye Research 2011, 36:1005-1013.
212. Seo K.Y., Han S.J., Cha H.R., Seo S.U., Song J.H., Chung S.H., Kweon M.N. Eye mucosa: an efficient vaccine delivery route for inducing protective immunity. Journal of Immunology 2010, 185:3610-3619.
213. Shields C.L., Markowitz J.S., Belinsky I., Schwartzstein H., George N.S., Lally S.E., Mashayekhi A., Shields J.A. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology 2011, 118. 389-395 e381-382.
214. Sivak J.M., Ostriker A.C., Woolfenden A., Demirs J., Cepeda R., Long D., Anderson K., Jaffee B. Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization. The Journal of Biological Chemistry 2011, 286:44965-44975.
215. Skobe M., Hamberg L.M., Hawighorst T., Schirner M., Wolf G.L., Alitalo K., Detmar M. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. The American Journal of Pathology 2001, 159:893-903.
216. Sonoda Y., Streilein J.W. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. Journal of Immunology 1993, 150:1727-1734.
217. Stacker S.A., Achen M.G., Jussila L., Baldwin M.E., Alitalo K. Lymphangiogenesis and cancer metastasis. Nature Reviews. Cancer 2002, 2:573-583.
218. Stein O., Dabach Y., Ben-Naim M., Halperin G., Stein Y. Lower macrophage recruitment and atherosclerosis resistance in FVB mice. Atherosclerosis 2006, 189:336-341.
219. Stern M.E., Siemasko K.F., Niederkorn J.Y. The Th1/Th2 paradigm in ocular allergy. Current Opinion in Allergy & Clinical Immunology 2005, 5:446-450.
220. Steven P., Gebert A. Conjunctiva-associated lymphoid tissue - current knowledge, animal models and experimental prospects. Ophthalmic Research 2009, 42:2-8.
221. Steven P., Rupp J., Huttmann G., Koop N., Lensing C., Laqua H., Gebert A. Experimental induction and three-dimensional two-photon imaging of conjunctiva-associated lymphoid tissue. Investigative Ophthalmology & Visual Science 2008, 49:1512-1517.
222. Steven P., Muller M., Koop N., Rose C., Huttmann G. Comparison of Cornea Module and DermaInspect for noninvasive imaging of ocular surface pathologies. J Biomed Opt 2009, 14:064040.
223. Steven P., Bock F., Huttmann G., Cursiefen C. Intravital two-photon microscopy of immune cell dynamics in corneal lymphatic vessels. PloS One 2011, 6:e26253.
224. Streilein J.W., Yamada J., Dana M.R., Ksander B.R. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplantation Proceedings 1999, 31:1472-1475.
225. Streilein J.W. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nature Reviews Immunology 2003, 3:879-889.
226. Streit M., Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003, 22:3172-3179.
227. Stuht S., Gwinner W., Franz I., Schwarz A., Jonigk D., Kreipe H., Kerjaschki D., Haller H., Mengel M. Lymphatic neoangiogenesis in human renal allografts: results from sequential protocol biopsies. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2007, 7:377-384.
228. Symes R.J., Poole T.R. Corneal graft surgery combined with subconjunctival bevacizumab (avastin). Cornea 2010, 29:691-693.
229. Teng C.C., Chin K.J., Finger P.T. Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension. British Journal of Ophthalmology 2009, 93:837-838.
230. Thiele W., Sleeman J.P. Tumor-induced lymphangiogenesis: a target for cancer therapy?. Journal of Biotechnology 2006, 124:224-241.
231. Truong T., Altiok E., Yuen D., Ecoiffier T., Chen L. Novel characterization of lymphatic valve formation during corneal inflammation. PloS One 2011, 6:e21918.
232. Van der Auwera I., Cao Y., Tille J.C., Pepper M.S., Jackson D.G., Fox S.B., Harris A.L., Dirix L.Y., Vermeulen P.B. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. British Journal of Cancer 2006, 95:1611-1625.
233. van Rooijen N., van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell and Tissue Research 1984, 238:355-358.
234. Vassileva P.I., Hergeldzhieva T.G. Avastin use in high risk corneal transplantation. Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2009, 247:1701-1706.
235. Veikkola T., Alitalo K. Dual role of Ang2 in postnatal angiogenesis and lymphangiogenesis. Developmental Cell 2002, 3:302-304.
236. Wardrop K.E., Dominov J.A. Proinflammatory signals and the loss of lymphatic vessel hyaluronan receptor-1 (LYVE-1) in the early pathogenesis of laminin alpha2-deficient skeletal muscle. Journal of Histochemistry & Cytochemistry 2011, 59:167-179.
237. Weingeist T.A. Fine structure and function of ocular tissues. The conjunctiva. International Ophthalmology Clinics 1973, 13:85-91.
238. Wenger R.H., Kvietikova I., Rolfs A., Camenisch G., Gassmann M. Oxygen-regulated erythropoietin gene expression is dependent on a CpG methylation-free hypoxia-inducible factor-1 DNA-binding site. European Journal of Biochemistry/FEBS 1998, 253:771-777.
239. Wessel J.M., Hofmann-Rummelt C., Kruse F.E., Cursiefen C., Heindl L.M. Invasion of lymphatic vessels into the eye after open globe injuries. Investigative Ophthalmology & Visual Science 2012, 53:3717-3725.
240. Whitcher J.P., Srinivasan M., Upadhyay M.P. Corneal blindness: a global perspective. Bulletin of the World Health Organization 2001, 79:214-221.
241. Whittle B.J., Moncada S., Vane J.R. Some actions of prostacyclin (PGI2) on the cardiovascular system and the gastric microcirculation. Acta biologica et medica Germanica 1978, 37:725-728.
242. Wigle J.T., Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999, 98:769-778.
243. Williams K.A., Coster D.J. The immunobiology of corneal transplantation. Transplantation 2007, 84:806-813.
244. Wu P.C., Kuo H.K., Tai M.H., Shin S.J. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 2009, 28:103-104.
245. Wuest T.R., Carr D.J. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis. Journal of Experimental Medicine 2010, 207:101-115.
246. Xu H., Chen M., Reid D.M., Forrester J.V. LYVE-1-positive macrophages are present in normal murine eyes. Investigative Ophthalmology & Visual Science 2007, 48:2162-2171.
247. Yamada J., Streilein J.W. Fate of orthotopic corneal allografts in C57BL/6 mice. Transplant Immunology 1998, 6:161-168.
248. Yamada J., Kurimoto I., Streilein J.W. Role of CD4+ T cells in immunobiology of orthotopic corneal transplants in mice. Investigative Ophthalmology & Visual Science 1999, 40:2614-2621.
249. Yamada J., Hamuro J., Fukushima A., Ohteki T., Terai K., Iwakura Y., Yagita H., Kinoshita S. MHC-matched corneal allograft rejection in an IFN-gamma/IL-17-independent manner in C57BL/6 mice. Investigative Ophthalmology & Visual Science 2009, 50:2139-2146.
250. Yamagami S., Dana M.R., Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea 2002, 21:405-409.
251. Yamashita J., Itoh H., Hirashima M., Ogawa M., Nishikawa S., Yurugi T., Naito M., Nakao K. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 2000, 408:92-96.
252. Yano K., Brown L.F., Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. Journal of Clinical Investigation 2001, 107:409-417.
253. You I.C., Im S.K., Lee S.H., Yoon K.C. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization. Cornea 2011, 30:30-33.
254. Yu C.Q., Zhang M., Matis K.I., Kim C., Rosenblatt M.I. Vascular endothelial growth factor mediates corneal nerve repair. Investigative Ophthalmology & Visual Science 2008, 49:3870-3878.
255. Yucel Y.H., Johnston M.G., Ly T., Patel M., Drake B., Gumus E., Fraenkl S.A., Moore S., Tobbia D., Armstrong D., Horvath E., Gupta N. Identification of lymphatics in the ciliary body of the human eye: a novel " uveolymphatic" outflow pathway. Experimental Eye Research 2009, 89:810-819.
256. Zhang D., Li B., Shi J., Zhao L., Zhang X., Wang C., Hou S., Qian W., Kou G., Wang H., Guo Y. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein. Cancer Research 2010, 70:2495-2503.
257. Zheng M., Deshpande S., Lee S., Ferrara N., Rouse B.T. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. Journal of Virology 2001, 75:9828-9835.
258. Zheng M., Schwarz M.A., Lee S., Kumaraguru U., Rouse B.T. Control of stromal keratitis by inhibition of neovascularization. The American Journal of Pathology 2001, 159:1021-1029.
259. Zhu S.N., Dana M.R. Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization. Investigative Ophthalmology & Visual Science 1999, 40:1427-1434.
260. Zhu W., Gilmour M.I. Comparison of allergic lung disease in three mouse strains after systemic or mucosal sensitization with ovalbumin antigen. Immunogenetics 2009, 61:199-207.
261. Zieske J.D. Perpetuation of stem cells in the eye. Eye 1994, 8(Pt 2):163-169.
262. Zimmermann P., Dietrich T., Bock F., Horn F.K., Hofmann-Rummelt C., Kruse F.E., Cursiefen C. Tumour-associated lymphangiogenesis in conjunctival malignant melanoma. British Journal of Ophthalmology 2009, 93:1529-1534.
263. Zirm E.K. Eine erfolgreiche totale Keratoplastik. Refractive & Corneal Surgery 1989, 5:258-261. 1906.